Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nick H Kim

Showing results (71-80 of 111) with videos related to

Pageof 12
Sort By:
The European Respiratory Journal|November 15, 2014
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2)Gérald Simonneau, Andrea M D'Armini, Hossein-Ardeschir Ghofrani, et al.
The Journal of Physiology|October 7, 2020
Abnormal pulmonary perfusion heterogeneity in patients with Fontan circulation and pulmonary arterial hypertensionSusan R Hopkins, Rui C Sá, G Kim Prisk, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|March 7, 2026
Methamphetamine-associated PAH on the Rise in the US: Geographic Trends & Disparities in Patient Demographics and Treatment StrategiesNick H Kim, Vinicio de Jesus Perez, John Kingrey, et al.
The New England Journal of Medicine|July 26, 2013
Riociguat for the treatment of chronic thromboembolic pulmonary hypertensionHossein-Ardeschir Ghofrani, Andrea M D'Armini, Friedrich Grimminger, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|August 6, 2021
Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertensionRaymond L Benza, Hossein-Ardeschir Ghofrani, Ekkehard Grünig, et al.
Pulmonary Circulation|April 22, 2024
NT-pro-BNP is predictive of morbidity and mortality after pulmonary thromboendarterectomy and is independent of preoperative hemodynamicsEmanuel A Keiler, Kim M Kerr, David S Poch, et al.
Heart (British Cardiac Society)|December 25, 2016
Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertensionNick H Kim, Andrea M D'Armini, Friedrich Grimminger, et al.
The Lancet. Respiratory Medicine|April 13, 2016
Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trialGérald Simonneau, Andrea M D'Armini, Hossein-Ardeschir Ghofrani, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|July 13, 2025
Diagnosis of chronic thromboembolic pulmonary hypertensionXavier Jais, Victor Tapson, Timothy M Fernandes, et al.
Journal of Thrombosis and Haemostasis : JTH|September 4, 2019
Sex-specific differences in chronic thromboembolic pulmonary hypertension. Results from the European CTEPH registryStefano Barco, Frederikus A Klok, Stavros V Konstantinides, et al.
Pageof 12

Showing results (71-80 of 111) with videos related to

Sort By:
Pageof 12
The European Respiratory Journal|November 15, 2014
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2)Gérald Simonneau, Andrea M D'Armini, Hossein-Ardeschir Ghofrani, et al.
The Journal of Physiology|October 7, 2020
Abnormal pulmonary perfusion heterogeneity in patients with Fontan circulation and pulmonary arterial hypertensionSusan R Hopkins, Rui C Sá, G Kim Prisk, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|March 7, 2026
Methamphetamine-associated PAH on the Rise in the US: Geographic Trends & Disparities in Patient Demographics and Treatment StrategiesNick H Kim, Vinicio de Jesus Perez, John Kingrey, et al.
The New England Journal of Medicine|July 26, 2013
Riociguat for the treatment of chronic thromboembolic pulmonary hypertensionHossein-Ardeschir Ghofrani, Andrea M D'Armini, Friedrich Grimminger, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|August 6, 2021
Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertensionRaymond L Benza, Hossein-Ardeschir Ghofrani, Ekkehard Grünig, et al.
Pulmonary Circulation|April 22, 2024
NT-pro-BNP is predictive of morbidity and mortality after pulmonary thromboendarterectomy and is independent of preoperative hemodynamicsEmanuel A Keiler, Kim M Kerr, David S Poch, et al.
Heart (British Cardiac Society)|December 25, 2016
Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertensionNick H Kim, Andrea M D'Armini, Friedrich Grimminger, et al.
The Lancet. Respiratory Medicine|April 13, 2016
Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trialGérald Simonneau, Andrea M D'Armini, Hossein-Ardeschir Ghofrani, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|July 13, 2025
Diagnosis of chronic thromboembolic pulmonary hypertensionXavier Jais, Victor Tapson, Timothy M Fernandes, et al.
Journal of Thrombosis and Haemostasis : JTH|September 4, 2019
Sex-specific differences in chronic thromboembolic pulmonary hypertension. Results from the European CTEPH registryStefano Barco, Frederikus A Klok, Stavros V Konstantinides, et al.
Pageof 12